Aktiesnakken — December 2011
-
nej lyder lidt hidsigt. men selv charity vil opsælge
-

-
satser og satser. Det er jo endnu en ting der begynder at køre i casen. Jeg vil tro at genmab først for alvor begynder at rykke når de omsætte de kliniske resultater i kolde kontanter
-
det er jo biotek.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind